Insurance by BogdanovaThe Encyclopedia of Insurance and Risk Science

RESEARCH DOSSIER

Voluntary Supplemental and Complementary Health Insurance

Abstract. Voluntary supplemental and complementary health insurance is a set of privately arranged risk-financing contracts whose function is determined by their interaction with statutory, tax-financed, or compulsory health entitlements. The same national label may conceal contracts covering residual cost sharing, services excluded from the main benefit package, upgraded amenities, faster access to overlapping services, or an alternative primary entitlement. This monograph establishes a comparative, source-traceable account of those functions, their contractual and actuarial mechanisms, the institutional pathways by which they influence service access, and their distributional consequences. It uses the OECD-Eurostat-WHO health-accounting architecture, comparative European Observatory scholarship, current official data and regulatory instruments from several jurisdictions, and original empirical studies. The analysis separates financing-scheme classification, the patient’s actual liability, provider allocation, insurer pool composition, and the identification of causal effects. Its formal decompositions show why an additional policy can lower a covered patient's payment at treatment without necessarily reducing household spending after premiums, total health expenditure, or inequalities in access. National cases exhibit contrasting configurations: regulated complementary cover in France, optional benefits around compulsory basic insurance in the Netherlands and Switzerland, duplicate hospital coverage in Ireland and Australia, standardized Medicare supplements in the United States, and Slovenia's transfer of former complementary financing into a compulsory contribution in 2024. Empirical findings establish conditional utilization and waiting-time associations but call for source-specific causal interpretation. The central conclusion is that institutional design, enrollment conditions, service capacity, risk pooling and the distribution of premiums jointly determine the effect of voluntary additional coverage. No new actuarial doctrine or general causal law is asserted.

Keywords: Voluntary health insurance; complementary health insurance; supplemental health insurance; supplementary health insurance; duplicate coverage; substitutive health insurance; health financing; statutory entitlements; cost sharing; financial protection; insurance economics; actuarial risk pooling; adverse selection; equity; access to care; comparative health systems; Medicare supplement; private health insurance.

Introduction

Additional health insurance becomes economically meaningful at the intersection of two systems: a preexisting set of healthcare entitlements and a second contract that changes who pays for, or how someone obtains, particular services. Defining the second policy merely by private ownership is insufficient. Some compulsory primary schemes are administered by private insurers, some voluntary arrangements are operated by mutual or public bodies, and some employer-sponsored complementary products are mandatory for employees. The European Observatory classification explicitly relates voluntary health insurance to statutory rights, financing and the configuration of publicly funded care. In turn, the System of Health Accounts framework classifies health expenditure by financing schemes rather than simply the legal form of the paying organization.

The research object is the additional or substitutive insured entitlement. Its basic unit is a relation between an individual or group, an underlying entitlement, a private contractual obligation, a healthcare service, and a financing transfer. A national description of private insurance must therefore answer five questions: who is entitled to baseline care; what risk or service gap is transferred; which entity promises payment; what access rights, if any, change; and which households ultimately finance the transfer. These questions also distinguish the study from separate monographs on universal health coverage, benefit-package priority setting, public subsidies, provider networks, insurance regulation, and adverse selection.

The international significance is substantial. The OECD 2025 coverage comparison observes widespread differences in the roles of additional insurance and explicitly cautions that formal coverage does not guarantee access. The WHO–World Bank 2025 monitoring report estimates that 2.1 billion people experienced hardship associated with out-of-pocket health expenditure in 2022, a global indicator with an entirely different population, denominator, and causal interpretation from voluntary policy ownership. The urgency of financial protection cannot justify treating the purchase of a private policy as an independently sufficient solution to systemic gaps.

The research strategy is comparative institutional reconstruction with formal accounting and selective empirical evaluation. A historical anchor is provided by Sagan and Thomson's 2016 role-and-regulation study and accompanying country-experience profiles; current cases are checked against later official administrative data, because the market and its legal rules have changed. The analysis gives exact attention to selection into insurance, provider capacity, fiscal intervention, premium incidence, and identification. Mathematical illustrations in this text are deterministic teaching examples and are not country estimates.

Conceptual, Historical, and Documentary Foundations

The legal entitlement precedes the supplemental contract

The baseline entitlement may arise through tax-financed residence rights, a social health insurance fund, compulsory private coverage, or eligibility for a public program. What matters for the additional contract is the set of covered persons, services, treatment settings, prices and payment obligations under this first layer. The baseline may itself include deductibles or coinsurance, impose provider-network limits, or exclude dental, optical or rehabilitative services. It can also contain waiting times that create a demand for alternative service channels. Consequently, the subject needs a relational description rather than a single universal definition of a supplemental insurance product.

The international health-accounting standard distinguishes compulsory financing schemes from voluntary healthcare payment schemes, including voluntary health insurance under HF.2.1. This accounting hierarchy must be kept separate from the OECD's role-based typology of complementary, supplementary and duplicate additional coverage. A scheme can be statistically voluntary yet serve as someone's primary financing source, and a contract can be legally private while mandatory to the purchaser. Conversely, the existence of a private supplementary insurer tells us little by itself about which claims fall within public health accounts or how its benefits overlap the core package.

Functional terminology and its boundaries

A complementary cost-sharing policy pays some or all of the insured patient's prescribed share of services already included in the primary package. A complementary service-gap policy may cover an excluded type of care; some European analyses group this with complementary cover, while the contemporary OECD presentation often calls it supplementary. Supplementary insurance, in the narrower benefit-extension sense, adds services, amenities or treatments not included in baseline coverage. Duplicate insurance purchases alternative access to services that are also nominally available through the public system, often involving a different provider, waiting time, location or amenity. Substitutive insurance takes the place of statutory cover for an eligible category of people who are excluded from, or may leave, the publicly financed scheme. These functions follow the historical Observatory functional explanation and the OECD's coverage definitions, with terminology harmonized explicitly for this analysis.

These roles do not exhaust contractual hybridity. A policy can reimburse the statutory deductible for one service, cover dental care beyond the statutory package, and enable a private hospital room under the same premium. Classification must identify the benefit component or establish a dominant purpose instead of attributing the entire product to one mutually exclusive group. The authors of the European comparative analysis emphasize the wide variation in market operation and regulation among countries. Their descriptions are evidence of historical arrangements, not a guarantee of their legal status a decade later.

Sources, periods and international comparability

The evidence hierarchy is deliberately heterogeneous. National legislation and official program notices establish the rules of eligibility and payment during the stated effective period; regulatory statistics measure membership, benefits and financing; the System of Health Accounts structures comparative expenditure; and epidemiologic or health-economics studies estimate associations or effects for defined samples. These records cannot be collapsed into an unconditional international average. For example, the OECD's cross-country figure distinguishes primary private insurance from additional private coverage and notes that its additional category is voluntary; its own discussion identifies employer complementary coverage mandates in France as a reason to treat the reported voluntary proportion carefully.

The comparative baseline is a fixed observation, not a universal constant. A 2016 European account may describe Slovenia's former complementary co-payment market; an independent Slovenian government notice documents that this arrangement was replaced by a compulsory contribution on January 1, 2024. A longitudinal study must code the date of the reform as a change in the treatment itself. Similarly, a French insured person receiving a means-tested publicly subsidized complement is not necessarily an economically or legally equivalent observation to a person buying an unsubsidized voluntary policy.

A documentary chronology of changed functions

The European Observatory's two 2016 volumes document mature private-health-insurance arrangements and their heterogeneous roles. A French employer-coverage mandate, recorded in the 2025 OECD explanatory notes, changed the voluntariness of a large segment of complementary cover. Slovenia's 2024 financing conversion altered a coverage function without implying that the clinical benefit basket disappeared. The 2025 and 2026 monitoring literature then observes coverage and financial protection under updated categories. These developments demonstrate an institutional fact: the functional identity of a healthcare payment can survive while its legal financing scheme changes, and the legal identity of a health insurer can persist while benefit composition changes.

Complementary Cost Sharing and Supplemental Services

Patient liability and the second payer

Consider a covered episode with an allowed charge A, statutory payment G, and residual charge R = max(0, A − G). Under a defined complementary contract, the private insurer pays C with 0 ≤ C ≤ R, subject to annual ceilings, exclusions, coordination rules and any deductible. In this stylized case the patient's payment on that episode is O = R − C. The equality is an accounting identity conditional on the specified allowed charge and on the absence of separate uncovered services, balance billing and additional fees. It is not a prediction of utilization or of the household's annual financial position.

For a real household, write T = P + O + U + F, where P is the household-borne premium net of a documented subsidy, O is eligible residual payment after complementary benefits, U is spending on uncovered services, and F represents other fees or billing differences. Each component must have a defined time horizon and the treatment episode must be correctly allocated. A policy may reduce O while increasing P and leaving U and F unchanged. Claims about lower total household expenditure require comparing the entire expression, not the out-of-pocket amount at the treatment counter.

Insurance also changes the distribution of financial risk. By paying P before uncertain treatment, the subscriber purchases a conditional benefit when the covered event occurs. Even if expected premiums exceed expected benefits because of administration, capital costs and underwriting margins, risk-averse households may value reduced volatility. The WHO financial-protection guidance explains why pooled prepayment can protect household consumption, especially relative to unpredictable point-of-care charges. The degree of protection depends on the exclusions and limits that remain after the policy's promise is read.

Price schedules, ceilings and provider bills

A cost-sharing complement may reimburse statutory copayments, a fixed percentage of allowed charges, a capped amount per service, or expenditure up to an annual limit. These devices interact with the primary system. Suppose the statutory system pays 80 percent of a defined eligible price of 100 monetary units and the patient owes 20. A contract that covers 100 percent of the statutory residual transfers 20 from the patient to the complementary insurer. If the provider charges 130 and 30 is excluded as an extra fee, the patient's final obligation may still include that 30 unless another contractual provision covers it. Saying that the complement covers the full copayment does not mean that the insurer covers every possible invoice amount.

Coverage on a reimbursement basis also differs from direct settlement. In the first case a patient may need cash to pay the provider and wait for reimbursement, retaining liquidity risk. In a direct-billing arrangement the providers coordinate statutory and complementary payments. Where patients face financing barriers, the administrative design can affect effective use even if nominal benefits are identical. The principle is especially relevant for low-income households and for policies reimbursing costly dental appliances or hospital extras.

French complementary finance and solidarity protection

France offers a prominent institutional example of second-layer cost-sharing cover. Complementary organizations include different organizational forms and are subject to financial reporting. The French official 2025 complementary-insurer financial report records EUR 46.5 billion in health contributions and EUR 36.8 billion in benefits for 2024, a 79 percent benefit-to-contribution ratio. These are aggregate accounting flows rather than an individual's payout ratio, a causal measure of access, or an exact estimate of administrative costs; the residual includes several uses of premiums and accounting items.

The means-tested Complémentaire santé solidaire (C2S) illustrates how a complementary layer can be publicly supported. The French government 2026 eligibility notice describes income-related access, either without member payment or at a low contribution, and updates the thresholds from April 1, 2026. In a comparison of voluntary supplemental finance, the relevant distinction is between the benefit function, which remains complementary, and the source of its funding, which differs by subsidy and eligibility. Merging these populations with self-financed purchasers would obscure both take-up mechanisms and the redistributive incidence of the system.

Additional benefits and contractual exclusions

The Netherlands provides a precise contrast. Its official basic-insurance guidance states that baseline health insurance is compulsory whereas additional insurance is optional and may cover services such as dental examinations that fall outside the basic package. A supplemental dental claim is therefore not necessarily a reimbursement of the patient's coinsurance on a service already paid by the statutory insurer. It can be a separately insured category of treatment with benefit schedules, annual limits, waiting conditions and premium rules.

Switzerland illustrates the strength of the separate contractual perimeter. The Federal Office of Public Health guidance identifies supplementary insurance as optional and subject to insurance-contract law; issuers are not compelled to offer it to all applicants. The FINMA supervisory description distinguishes private supplementary supervision from the compulsory basic insurance system. This division matters because guaranteed issue and uniform public benefits in basic insurance cannot simply be presumed for supplemental policies. The insured's premium and available benefits may depend on underwriting or contractual eligibility that would be treated differently in the basic layer.

Premium equivalence and risk pooling

For a defined portfolio of N insured contracts, an elementary ex ante premium identity is P_bar = (E[B] + E[A] + E[K]) / N, where B denotes aggregate contractual benefits, A expected administration and distribution, and K the expected cost of capital or other explicitly modeled loads. This is an illustrative break-even decomposition, not a universal regulatory pricing equation: investment income, taxes, mutual surplus, subsidies, risk equalization and changing enrollment can affect actual rates. The underwriting problem must also consider correlation between claim costs, lapses, service-price inflation and utilization induced by the benefit schedule.

A contract covering low-frequency large residual bills and one covering frequent inexpensive dental checkups may generate similar annual expected benefits yet very different risk reduction. For a frequent and predictable service, much of the premium can resemble a payment-plan transfer, with a lower pure insurance function. For rare severe financial shocks, pooled indemnity can protect consumption more substantially. This distinction makes an economic evaluation of supplemental policies dependent on the loss distribution and household liquidity, rather than on benefit labels.

Selection and endogenous health spending

If people can buy a more generous policy after anticipating a dental procedure, coverage choices and expected claims are jointly determined. Complementary insurers may respond through waiting periods, benefit caps, enrollment windows, employer-group arrangements, or underwriting where allowed. An observed difference in claims between generous-plan buyers and basic-plan buyers combines preexisting needs, prior expectations, supply conditions and any incentive effect of lower marginal prices. The original French quasi-natural insurer study illustrates this problem directly: consumption increased for some expensive services after enhanced coverage, but higher consumption was visible before switching as well.

Thus the analysis separates insurer adverse selection, household sorting, ex post responses to reduced marginal prices, and clinical catch-up after unmet needs. All are mechanisms consistent with changed utilization; none is correctly identified by a single post-enrollment claims difference alone.

Duplicate and Substitutive Market Forms

Duplicate coverage changes a service pathway

Duplicate health insurance provides an alternative financing and access path for services the publicly financed system also covers. The patient may seek treatment at a private facility, consult a particular clinician, avoid some waiting lists, or receive hospital accommodation above the public standard. In this case the principal object being purchased can be scheduling or provider choice as much as reimbursement of a residual statutory bill. The functional definition follows the OECD additional-coverage typology. An episode financed privately may be clinically similar to a publicly available procedure while differing in timing, provider and facility.

A duplicate policy does not automatically increase aggregate surgical or specialist capacity. In a system with separately funded spare capacity it may direct utilization toward additional facilities. Where the same specialists, operating rooms or diagnostic equipment serve both sectors, shifting activity toward insured private patients may change priority and queues without increasing total system output. The empirical question is therefore the net effect on access for insured and uninsured patients together, accounting for resource constraints and spillovers.

Ireland: regulation and observed waiting-time differences

Ireland offers an example of substantial inpatient private coverage alongside a public care system. The Health Insurance Authority's open-enrollment rules require private insurers to accept applicants subject to prescribed waiting periods, while lifetime cover protects renewability in ordinary circumstances. Its lifetime community-rating guidance describes late-entry premium loadings that encourage earlier participation. Regulation modifies the market's selection and premium dynamics; it does not guarantee equivalent access between private policyholders and patients relying on public pathways.

Whyte, Connolly and Wren (2020), in an original Irish waiting-time analysis, examined 2007 and 2010 household survey data. The abstract reports a greater share of people without private insurance waiting more than three months for hospital-based services, without evidence that the attempted common-waiting-list reform narrowed the differential. The study identifies an association in a particular historical period, with implementation and capacity confounders, rather than a transferable estimate of what one additional private policy would cause in present-day Ireland.

Australia: separate hospital and general-treatment functions

Australia combines Medicare with voluntary private hospital and ancillary markets. In the June 2026 insurer statistics, hospital treatment cover extended to 12,823,752 persons, 45.8 percent of the population; general treatment cover extended to 15,525,399 persons, 55.5 percent. These are different product categories with overlapping members, so adding the two counts would double-count people. Hospital cover relates strongly to duplicate institutional pathways, whereas general-treatment policies can cover benefits such as dental and optical care outside the principal Medicare arrangements.

Australia's demand incentives are unusually explicit. The 2026–27 surcharge schedule sets income-sensitive Medicare levy surcharge rates for qualifying circumstances without appropriate private patient hospital cover. The Lifetime Health Cover rules use age-of-entry loadings to encourage earlier hospital insurance enrollment. These mechanisms can change the population entering the market and should be represented as policy-induced price changes, not as intrinsic consumer preference. The effect of a tax-based insurance incentive on the public budget also depends on foregone revenue or subsidies, use of private and public services, and insurer/provider responses. A higher insured share alone does not establish fiscal saving.

Substitutive insurance and the statutory boundary

Substitutive coverage differs conceptually because it replaces a person's ordinary public or compulsory entitlement rather than simply overlapping or extending it. The Observatory's substitutive definition identifies circumstances in which persons are excluded from publicly financed coverage or allowed to choose between private and statutory schemes, including certain German arrangements in the study's comparative context. Researchers must identify the governing eligibility law, which populations are permitted or required to switch, and whether return to statutory coverage is constrained.

The substitutive distinction matters for pooling. If more affluent or lower-risk groups can move outside the statutory pool without equivalent solidarity transfers, the distribution of contributions and risk can change. If statutory eligibility, taxes and risk adjustments already preserve cross-subsidy, the same nominal act of private purchase has a different financing incidence. The analysis is one of exact legal and financial flows rather than a presumption that substitution necessarily drains or necessarily helps public financing.

The American Medigap boundary

In the United States, Medicare Supplement Insurance, or Medigap, is a particularly clear complementary cost-sharing form associated with Original Medicare rather than a replacement of Medicare. The federal Medigap guidance identifies standardized policies that help pay eligible copayments, coinsurance and deductibles. It should not be conflated with Medicare Advantage, separate dental policies, employer insurance or the entirety of US commercial health insurance.

Availability and underwriting rights are time-specific. Under the federal Medigap enrollment rules, an eligible person aged 65 or older who has Medicare Part B receives a six-month open enrollment period in which protections against medical underwriting apply, subject to the stated federal conditions. After that period, federal guaranteed purchase rights are narrower, with additional protections varying by circumstances and state. Access analysis must therefore include acquisition and switching constraints, not merely the availability of standardized benefits.

Slovenia's financing conversion

Slovenia supplies an important institutional counterfactual in classification. The December 2023 government announcement states that voluntary complementary insurance previously meeting copayments was replaced from January 1, 2024 by a compulsory health contribution, while the relevant benefit package was financed within the statutory arrangement. A before-and-after count of voluntary insurance would mechanically decline even if people continued receiving broadly comparable insured care. The reform changed who collects and pools contributions, and the legal financing scheme; any stronger conclusion about clinical access, household incidence or fiscal efficiency requires subsequent evidence, not the announcement alone.

This case also exposes the risk of treating markets as natural categories. A compulsory mechanism can assume the role of an earlier voluntary private mechanism. Researchers estimating the consequences of 'private insurance penetration' must model policy recoding, eligibility, subsidies, provider rules and changing utilization before assigning a substantive welfare meaning to the coverage series.

Effects on Access and Inequality

Insurance ownership is a selective exposure

The socioeconomic distribution of voluntary coverage reflects the affordability of premiums, occupational benefits, health risk, provider availability and knowledge of enrollment options. Premium subsidies and employer contributions can modify these relationships without eliminating them. Sagan and Thomson's cross-European distributional synthesis reports that voluntary markets differ substantially, and raises concerns about equitable access, administrative efficiency and accountability even where regulated. Their caution concerns institutional variation, not a claim of a uniform negative effect in every country.

The difference between possession of a policy and actual protection is essential. Someone may be enrolled but face an exclusion or benefit ceiling; another may lack private insurance while receiving comprehensive cost-free statutory care. A person may hold duplicate hospital cover yet experience long waits because private specialist supply is limited. Studies comparing utilization must therefore measure actual benefits and the relevant services, not just a binary self-reported ownership variable.

Access, utilization, waiting times and outcomes

Access has several observable dimensions: eligibility to receive a service, affordability of out-of-pocket payments, travel and appointment availability, wait time, treatment received, service quality and health outcomes. Utilization is an imperfect proxy for access, because it combines clinical needs, preferences, physician incentives and supply. The WHO financial-protection framework ties financial protection to the capacity to obtain needed care without unacceptable household sacrifice; that concern cannot be reduced to the number of insured people.

A change in complementary reimbursement can increase expenditure because additional needed care becomes affordable, because patients advance previously delayed treatments, because providers recommend higher-intensity care when reimbursement rises, or because enrollment was selected in anticipation of treatment. The welfare interpretation differs across these channels. A policy evaluation should link service units, clinical indication and final patient liability whenever data permit, and distinguish higher use of beneficial care from higher prices for identical services.

French quasi-experimental evidence

Sevilla-Dedieu, Billaudeau and Paraponaris (2020) used insurer claims from 85,541 persons between 2009 and 2018 in their French complementary-plan comparison. Matching and difference-in-differences estimated changes associated with switching from basic to extended coverage. The paper reports a particularly marked, mostly first-year increase for costly dental prostheses and optical care, but documents pre-switch increases as well. The defensible conclusion is that plan generosity and observed utilization co-move in a way consistent with both catching up on care and selection; the precise causal partition remains difficult.

Carré, Jusot and Wittwer (2026) address a different intervention in their CMU-C access study: enrollment in a means-tested, publicly financed complementary arrangement. Their administrative-data analysis, using staggered differences and strategies addressing enrollment selection, finds increased use at extensive and intensive margins, with important responses among previously uninsured individuals. This result is a finding for a targeted low-income policy under a specified French framework. It does not imply that an unsubsidized commercial policy sold at a risk-rated premium would generate the same incidence or welfare effects.

The two studies jointly support a nuanced interpretation. Lower residual prices can increase use, but the identity of those obtaining the benefit and the meaning of the increase depend on eligibility, timing, unmet need, clinical risk and selection. The historical CMU-C designation in an empirical article must also remain distinguishable from the later C2S program rules documented by the 2026 French eligibility guidance.

Observational international inequality

Baggio, Dupuis, Wolff and Bodenmann (2018) examine the associations of private coverage and inequality across universal-coverage contexts. Cross-country and longitudinal observations can reveal inequalities and correlates of insufficient protection, but differences in national benefit baskets, self-selection into policies and unobserved health needs complicate a single causal reading. The key methodological distinction is between describing how coverage and hardship cluster within groups and identifying what changing a particular policy would do to those groups.

The global 2025 UHC monitoring evidence further prevents a common denominator error. The 2022 worldwide hardship estimate concerns all forms of out-of-pocket burden, including health systems where voluntary supplementary insurance has little market reach. It measures a need for financing protection; by itself it provides no effect size for a voluntary health-insurance reform.

An original transparent numerical illustration

Consider two socioeconomic groups with 100 individuals each and annual public-system residual care liabilities fixed, for illustration, at 400 monetary units for each person in Group L and 600 in Group H. Suppose voluntary complementary coverage reimburses exactly half the residual liability, its take-up is 20 percent in L and 80 percent in H, and a uniform annual policy premium is 300. Assume every liability is incurred, treatment prices and behavior are held fixed, and no subsidy applies. These assumptions are intentionally stylized: the group-specific liabilities represent certain amounts here, not true uncertain risk distributions.

Illustrative quantity Group L Group H
People 100 100
Liability without complementary cover per person 400 600
Insured proportion 20% 80%
Complementary benefit for each insured person 200 300
Expected per-person residual payment after coverage 360 360
Expected per-person premium paid across group 60 240
Combined annual patient payment and premium per person 420 600

The low-income group purchases fewer policies and therefore receives less insured reimbursement per capita: 40 versus 240 monetary units. Across the entire hypothetical portfolio, total benefits are 20 × 200 + 80 × 300 = 28,000, while total collected premiums equal 100 × 300 = 30,000; the remaining 2,000 is a hypothesized gross loading before detailed costs. In this deliberately risk-free example the premium finances a reimbursement transfer rather than genuine volatility reduction; an authentic insurance value calculation would introduce stochastic losses and risk preferences.

The calculation shows three analytically distinct statements. First, equal expected residual patient charges of 360 per person do not establish equal overall financial burden: premiums differ sharply by group participation. Second, a higher take-up rate generates greater transfer of eligible expense to the supplemental insurer without proving a greater clinical need met. Third, the pooled income and claim distribution can be arithmetically reconciled while the policy fails to lower aggregate expected private spending, because the insurance layer has administrative cost. None of these numbers is presented as observed in France, Australia, Ireland or any other country.

Two-sided distributional accounting

For the overall health-financing system, a policy's distributional effects are determined jointly by household premiums, public subsidies, tax financing, changes to statutory expenditure, provider prices and the quantity of care. A voluntary plan purchased mainly by higher earners can still indirectly benefit lower earners if its financing expands clinical capacity shared with the public system. It may instead increase waiting times in a shared-capacity market. Either conclusion requires observation of the provider-side counterfactual.

The correct distributional unit varies with the question. Person-level coverage can measure enrollment inequality; family-level disposable income can measure affordability; expenditure deciles and clinical-need strata can measure payment burden; regions can measure specialist availability. An equity inference that changes units midway through an argument risks attributing household effects to individual insurance decisions or national averages to local access.

Data, Model Validation, and Research Identification

A reproducible unit-of-analysis protocol

A defensible dataset should record the policy unit, person identifier, household attributes, statutory entitlement, date of exposure, policy entry and exit, premium, employer or state contribution, defined service, gross provider charge, statutory payment, insurer supplemental benefit, remaining patient charge, and service date. For duplicate policies it must also capture waiting time, provider type, treatment priority, physical capacity and public/private pathway. For substitutive policies it must record statutory eligibility, contribution transfers and switching restrictions.

Different data sources observe different subsets of this information. Insurer claims typically reveal reimbursed use and benefits among enrolled members, while offering limited visibility into uninsured people and services paid entirely out of pocket. Household surveys cover broader populations but may misstate premium amounts, health status, waiting periods and exact contract benefits. Administrative records can track enrollment more accurately, yet they may lack household earnings or private provider invoices. These limitations cannot be erased by larger samples if the required counterfactual variable is missing.

Health-financing accounting and source reconciliation

The SHA 2011 revised classification provides a consistent accounting language for scheme-based current health expenditure. For a precisely defined expenditure aggregate, one may write total current health expenditure as the sum of amounts financed through government/compulsory, voluntary health insurance, household out-of-pocket and other financing schemes, observing the official category definitions and avoiding reimbursement double counting. Premium contributions are not themselves the same quantity as care financed in a given accounting period; claims-based benefits, insurer reserves and contributions have different timing and measurement.

Published insurer financial statements have their own denominator. The French 2024 claims and contributions figures give contributions of EUR 46.5 billion and benefit payments of EUR 36.8 billion. Their ratio is approximately 0.7914, or 79.1 percent before rounding; the officially published 79 percent ratio is consistent. This does not mean that 21 percent is profit. Administration, acquisition, prudential arrangements, timing and other accounting components can occupy the difference. The calculation illustrates a numerical cross-check against the source without inventing an actuarial data model.

Causal estimands and identification

The causal effect of purchasing an additional policy requires specifying what is held fixed and what is allowed to respond. For a household outcome Y, an individual average treatment effect E[Y(1) − Y(0)] differs from an intent-to-treat effect of eligibility or a subsidy, and from a whole-system equilibrium effect in which public and private provider allocation changes. A voluntary purchase is generally chosen with information about expected needs, financial resources and employer participation. Simple insured-versus-uninsured differences are confounded by these variables.

Difference-in-differences designs compare changes under an assumed untreated counterfactual trend. They require attention to pre-treatment trajectories, the timing of adoption, heterogeneous effects and anticipatory purchasing. The pre-switch consumption patterns in the French study are an empirical reminder that a policyholder may already expect higher expenses. Carré and colleagues' means-tested enrollment estimates use a different identification strategy and treatment population; their design should be evaluated on its own administrative-data assumptions. The two studies should not be averaged as if estimating the same intervention.

Instrumental variables require a defensible exclusion restriction and a precisely defined compliers' population; eligibility discontinuities need checks for manipulation and continuity; randomized encouragement designs require attention to uptake and spillovers. In a duplicate hospital market, interference between patients is a central problem: private enrollment may affect a non-enrollee's waiting time. An individually randomized estimand can consequently miss the policy's general-equilibrium effect.

Measurable inequality outcomes

The following measures answer different scientific questions. Enrollment prevalence is the share of a defined population holding a qualifying policy, with a date and type of cover. The residual-payment rate is the uncovered patient amount divided by a specified eligible bill or income base; it is not a universal health accounts ratio. Impoverishing out-of-pocket payment compares care costs with a poverty threshold and household resources. Waiting-time distributions require the same clinical urgency and treatment pathway. Unmet need requires a consistent self-reported or clinically defined need, not just zero utilization.

For quantitative equity work, one may estimate policy take-up by income quintile, compare conditional out-of-pocket distributions, and calculate concentration or inequality indices with documented survey weights. Need-standardized service use can be contrasted by coverage class, but a need model introduces its own measurement assumptions. Every indicator should specify numerator, denominator, country, year, sample exclusions, coverage function and treatment of missing values. The OECD comparability notes demonstrate why additional private coverage percentages cannot be interpreted without their definitions.

Robustness and falsification

A complete empirical test should vary definitions of supplementary versus duplicate cover, include and exclude subsidized contracts as separate populations, assess concurrent policy reforms, and estimate effects across income, age, morbidity, employer status and geographic access. It should test pre-trends and event timing, report policy lapses and switchers, and examine costs alongside service quantities. In the Australian setting, the separate hospital and general-treatment counts make clear that total coverage must be deduplicated at person level before calculating a combined insured prevalence.

Institutional reform deserves a specific form of measurement audit. The 2024 Slovene financing conversion would generate a classification discontinuity even with a stable benefit basket. An evaluator must report both an unadjusted legal-scheme series and a functionally harmonized care-entitlement series, or provide a clear crosswalk. Otherwise a fall in voluntary insurance can be mistaken for deterioration in protection.

Evidence limitations and source integrity

This research checks official descriptions, selected current administrative releases, publisher bibliographic/abstract pages and accessible scholarly texts. It does not perform restricted-claims-data replication, individual-country complete statute-by-statute legal advice, network-wide real-time access testing, or a new meta-analysis. The manuscript's numerical illustration is independently arithmetically reproducible from stated assumptions. Official contemporary sources are used for present administrative claims, while published studies retain their historical sample and intervention dates. The linked bibliography is a record of documents actually consulted for the stated claims, not an assertion that every paywalled page was read in full.

Integrated International Synthesis and Research Conclusions

Institutional comparisons

The comparative cases resolve into distinct financing and access patterns. In France, second-layer reimbursement and targeted assistance interact with statutory entitlements; the principal access mechanism often runs through the residual price paid by the patient. In the Netherlands, optional benefits sit outside a compulsory standard package. In Switzerland, optional supplementary insurance constitutes a distinct contract-law and supervisory domain. In Ireland and Australia, private hospital policies can change treatment pathways and provider options relative to a public entitlement. In the United States, Medigap is a deliberately standardized complement to Original Medicare. In Slovenia, a previously private complementary financing function was converted to a compulsory statutory contribution.

The cases show why treating all additional policies as a single exposure would be analytically misleading. They also identify a common structure: each arrangement reallocates financing, rights or provider access across an existing entitlement boundary. The empirical effects follow from the exact boundary and applicable market rules. A complementary dental schedule, an inpatient private-bed policy, and a substitutive primary medical policy have different counterfactuals, risk pools and likely beneficiaries even though each may be described informally as private health insurance.

Fiscal and insurer consequences

The state's fiscal incidence depends on whether voluntary policies are subsidized, tax-favored, mandatory for certain groups, or entirely privately financed. Public expenditure may rise when subsidized coverage encourages beneficial treatment or when private reimbursements interact with statutory tariffs; it may fall if a service is demonstrably transferred away from public budgets without offsetting subsidies or spillovers. Neither direction can be inferred from the ratio of private members to total population alone. Australia's surcharge rules illustrate a fiscal incentive to enroll, whereas France's targeted solidarity scheme shows an income-related route to second-layer coverage.

The insurer's actuarial position is likewise conditioned on selection rules, benefit generosity and expected losses. Open enrollment and renewal protection, documented for Ireland by the regulatory authority, limit exclusion of applicants; premium loading and other permitted mechanisms change who joins and when. Under risk-rated contracts, sorting can be more direct, as the Swiss supplemental eligibility rules illustrate. Premium regulation should be evaluated alongside risk transfers and market entry, rather than in isolation from pool composition.

Practical interpretation of the research evidence

The strongest transferable conclusion is conditional: when a private supplemental benefit genuinely reimburses part of an eligible patient bill, the eligible patient's direct payment for that bill falls by the reimbursement amount, holding other charges constant. This is an accounting result. A broader improvement in the person's financial protection depends on premiums, uncertainty, claim limits, eligibility and the distribution of illness. A causal increase in useful care additionally depends on clinical need, provider capacity and the response to lower marginal prices. Changes in waiting-time equity require measuring the experience of both insured and uninsured patients.

The empirical record supports careful rather than automatic attribution. The French coverage-change study demonstrates a utilization response intertwined with anticipation and selection; the French low-income subsidy study identifies an effect for a distinctive targeted public intervention; the Irish waiting-time study finds historical differences with implementation caveats. These are different estimands, samples and periods. Taken together they justify specific hypotheses for future national evaluation rather than a universal coefficient or an original general theory.

Research agenda from the observed gaps

Several questions remain empirically testable. First, when does an additional policy reduce catastrophic financial burden after net premiums and subsidies rather than merely shifting the timing of payment? Second, how does access change for the uninsured when duplicate private capacity uses clinicians shared with public services? Third, which restrictions on underwriting, switching and waiting periods improve enrollment equity without destabilizing insurer pools? Fourth, do fiscal incentives expand private clinical capacity or principally increase payment for services that would have occurred through statutory provision? Fifth, how should cross-country time series be adjusted when a complementary financing function becomes compulsory?

These questions require linked administrative, insurer, provider and household evidence. The present synthesis establishes the variables, legal distinctions and source-sensitive inferential boundaries that such empirical investigations must maintain. Its purpose is methodological clarity and a comparative understanding of existing institutions.

Conclusion

Voluntary supplemental and complementary health insurance is an institutional relation between a primary healthcare entitlement and a secondary risk-financing or access contract. The decisive distinctions concern residual cost-sharing protection, additional service benefits, duplicate treatment routes and substitution for statutory eligibility. International sources show that these functions differ in regulation, financing, underwriting and population reach, and that the same function can migrate between voluntary and compulsory financing categories.

The accounting effect of complementary benefits on an eligible episode can be determined exactly when the claim rules are specified. The household welfare, national fiscal, service-use and equity effects require additional evidence about premiums, subsidies, medical needs, selection and available provider capacity. The most credible empirical studies distinguish these mechanisms through explicit samples and identification strategies, while preserving the limits of each estimate. Financial protection is therefore assessed at household and health-system levels rather than inferred solely from insurance enrollment.

The comparative evidence supports a precise scientific conclusion: additional private insurance can deliver valuable risk pooling or improve access under particular institutional conditions, while its costs and access advantages can be distributed unequally. The assessment of any arrangement must identify the counterfactual statutory right, the exact benefit transferred, the financing incidence and the effects on persons who remain outside the voluntary market. This conclusion is an original integrated reading of established classifications, official records and empirical research. It introduces no new authorial theory, doctrine or universal model.

References